Dear Editors:  
On behalf of my co-authors, I am submitting the enclosed material “Inhibition of BRAF sensitizes papillary thyroid carcinoma to immunotherapy by abrogating the TGF-β1/SMAD3-tsMHCII mediated immune escape” for possible publication in Theranostics.

We believe that two aspects of this manuscript will make it interesting to general readers of your journal. First, we uncover a novel immune escape mechanism in advanced PTC. BRAFV600E down-regulates the expression of tsMHCII through TGF-β1/SMAD3 pathway, and enhances the immune escape ability of tumors. More importantly, upregulating tsMHCII by BRAF inhibitor enhances the response and sensitivity to anti-PD-L1 antibody treatment *in vivo* and *in vitro*, which suggests that combined therapy of immunotherapy and small molecule inhibitor could be an effective therapeutic strategy for related PTC. In brief, PLX4032 up-regulated tsMHCII enhances the recognition and elimination effects of immune system with anti-PD-1 antibody treatment, combination of BRAF inhibitor and anti-PD-1 antibody has potential implications for PTC treatment.  
We certify that we have participated sufficiently in the work to take public responsibility for the appropriateness of the experimental design and method, and the collection, analysis, and interpretation of the data.

We have reviewed the final version of the manuscript and approved it for publication. To the best of our knowledge and belief, this manuscript has not been published in whole or in part nor is it being considered for publication elsewhere.  
  
Best Regards.  
Yours Sincerely,

Ming Gao

Headandneck2008@126.com